Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 1999
The purpose of this study is to see if it is safe and effective to give zintevir (AR177) to asymptomatic (no symptoms) HIV-infected patients. Zintevir belongs to a new class of anti-HIV drugs, the integrase inhibitors. HIV uses the protein integrase to infect a cell. Integrase inhibitors block integrase and may stop replication of HIV.
Epistemonikos ID: c5f2f830b5a9213a7fe5edf1647ebe3bff1ba9de
First added on: May 03, 2024